Dr.  Jamil has spent nearly two decades leading drug development across various stages of clinical trials in the pharmaceutical industry. His primary focus of research has been in areas of high unmet need and include Hepatology, critical care, and transplant among other therapeutic areas. He joined the industry as part of the late-phase trials for Sugammadex at Organon which led to the first approval of a neuromuscular blockade in general anesthesia. He later joined Ikaria and served in a translational science role managing multiple molecules in early-phase development. Most recently he served as Vice President of Hepatology at Mallinckrodt and led the team through FDA approval of Terlipressin, a first-ever approval for complication of cirrhosis i.e. Hepatorenal Syndrome.

During his career, Dr. Jamil has led multiple new drug application filings and secured approvals from regulatory agencies such as the FDA, EMA, TGA, and PMDA. He is the holder of multiple patents that are a testament to the innovative trial designs that led to novel findings. He has moderated and participated in FDA advisory committee meetings and has been part of global consensus meetings for complications of cirrhosis and clinical trial endpoints. He also served in a medical affairs role and played a pivotal role in shaping communication strategies that have led to updates in clinical guidelines and a paradigm shift in patient management within the healthcare community. Dr. Jamil also has extensive experience in establishing the burden of disease and the cost-effectiveness of newly approved therapies.

A graduate of a leading medical school in Pakistan, King Edward Medical University; Dr. Jamil completed his residency training at Seton Hall University and held academic research positions before joining the industry. He lives with his wife and daughter in Bucks County, Pennsylvania.